Recently, several examples of foldamers have been reported containing a mixture of alpha,beta-amino acids in alternating order. In several cases, an increased resistance of the pseudopeptides against proteases was indicated in comparison to their native counterparts. Here, we report on the synthesis of novel foldamers with the general formula Boc-[(S)-beta3-hPhg-D-Oxd]n-OR, where (S)-beta3-hPhg is the abbreviation for (S)-beta3-homophenylglycine and D-Oxd that for trans-(4R,5S) 4-carboxy-5-methyl oxazolidin-2-one.

G. Angelici, C. Tomasini (2007). Synthesis an Secondary Structure of Alternate alpha,beta-Hybrid Peptides Containing Oxazolidin-2-one Moieties. s.l : s.n.

Synthesis an Secondary Structure of Alternate alpha,beta-Hybrid Peptides Containing Oxazolidin-2-one Moieties

ANGELICI, GAETANO;TOMASINI, CLAUDIA
2007

Abstract

Recently, several examples of foldamers have been reported containing a mixture of alpha,beta-amino acids in alternating order. In several cases, an increased resistance of the pseudopeptides against proteases was indicated in comparison to their native counterparts. Here, we report on the synthesis of novel foldamers with the general formula Boc-[(S)-beta3-hPhg-D-Oxd]n-OR, where (S)-beta3-hPhg is the abbreviation for (S)-beta3-homophenylglycine and D-Oxd that for trans-(4R,5S) 4-carboxy-5-methyl oxazolidin-2-one.
2007
XXXI Convegno Nazionale della Divisione di Chimica Organica della Società di Chimica Italiana ATTI
PF1
PF1
G. Angelici, C. Tomasini (2007). Synthesis an Secondary Structure of Alternate alpha,beta-Hybrid Peptides Containing Oxazolidin-2-one Moieties. s.l : s.n.
G. Angelici; C. Tomasini
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/57630
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact